InVirtuoLabs
- Company typePrivate
- Founded2024
- HeadquartersLugano, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
InVirtuoLabs firmographics
Firmographics- Name
- InVirtuoLabs
- Legal name
- InVirtuoLabs SA
- Website
- https://invirtuolabs.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
InVirtuoLabs industry classification
Industry- Product category
- AI Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Cheminformatics & Molecular Modeling / CADD (HLAGAJAE), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where InVirtuoLabs is headquartered
LocationHeadquarters
- HQ city
- Lugano
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
InVirtuoLabs business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- AI Platform Licensing & Co-Development: Revenue generated through strategic R&D collaborations with pharmaceutical companies where InVirtuoLabs applies its AI platform to design, optimize, and prioritize drug candidates. Partners like Helsinn provide proprietary compound libraries while InVirtuoLabs delivers optimized lead compounds for preclinical development.
- Eurostars Research Grant: Non-dilutive funding from €2.3M Eurostars grant for NEUROSPARK project targeting rare neurodegenerative disorders, with potential expansion to Alzheimer's and Parkinson's treatments.
- EuroHPC Access Grant: EuroHPC JU AI Large Scale Access grant providing 2,000,000 GPU-hours (worth ~€3M) on LUMI-G supercomputer for MASH liver disease research.
Go-to-market motion3 records
Distribution channels1 record
Marketing channels6 records
InVirtuoLabs product offering
Product offeringCore offering
InVirtuoLabs builds and operates the InVirtuo Platform, an AI-powered end-to-end drug discovery system that combines multimodal learning, active learning, and generative chemistry with physics-based molecular simulations. The platform is delivered as three integrated modules — InVirtuoMOL (molecular property evaluation ML engine), InVirtuoGEN (multimodal generative AI for novel molecule design, capable of generating 1 billion molecules per day), and InVirtuoSIM (physics-based modeling of drug-target interactions) — applied through co-development partnerships with pharmaceutical and biotech companies to identify and optimize preclinical drug candidates.
Product overview
InVirtuoLabs offers a modular AI-powered drug discovery platform called the InVirtuo Platform, which integrates three core modules: InVirtuoMOL (molecular ML engine for property evaluation), InVirtuoGEN (multimodal generative AI for molecule design), and InVirtuoSIM (physics-based simulations for molecular interaction analysis). The platform aims to dramatically accelerate drug discovery by combining machine learning with physics-based simulations to explore chemical space efficiently.
Differentiator
Problem solved
Functional benefit
Brands
- InVirtuo Platform: End-to-end AI-powered system for drug discovery combining machine learning with physics-based molecular simulations.
- InVirtuoMOL
- InVirtuoGEN
- InVirtuoSIM
Products and services
- InVirtuo Platform End-to-end AI-powered system for drug discovery that combines multimodal learning, active learning, and generative chemistry with physics-based molecular simulations. Used by pharmaceutical and biotech partners for target validation, hit discovery, lead optimization, and preclinical validation of drug candidates.
- InVirtuoGEN Open-Source Results and Pretrained Checkpoints Open-source release of the InVirtuoGEN generative chemistry model with pretrained checkpoints, benchmarks, and reproducible results on GitHub, enabling academic and developer community to validate and build on the platform's generative chemistry capabilities.
Quantifiable outcome
- 90% reduction in molecular property processing time with InVirtuoMOL
- +5 more outcomes
Companies that use InVirtuoLabs
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
InVirtuoLabs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
InVirtuoLabs partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered major, core, flagship and supporting.
- EuroHPC JUmajorEuroHPC JU AI Large Scale Access grant providing 2,000,000 GPU-hours (worth ~€3M) on LUMI-G supercomputer to advance AI-driven search for MASH treatment.
- Helsinn Healthcare SAcoreStrategic R&D collaboration where Helsinn provides access to its proprietary library of structurally diverse compounds with confirmed biological activity against an undisclosed therapeutic target, while InVirtuoLabs applies its AI-driven generative chemistry platform InVirtuoGEN to design, optimize, and prioritize novel drug candidates for preclinical development in oncology and chronic disease indications. Collaboration aims to leverage next-generation AI technology to accelerate drug discovery and deliver therapeutic solutions to patients.
- 7hc (Italy)coreItalian partner in the €2.3 million Eurostars NEUROSPARK project focused on identifying and validating lead molecules for treating rare neurodegenerative disorders using AI-based Virtual Cell Models.
- INSYBIO (Greece)coreGreek partner in the €2.3 million Eurostars NEUROSPARK project focused on AI-based Virtual Cell Models for neurodegenerative drug research.
- oloBion (Spain)coreSpanish partner in the €2.3 million Eurostars NEUROSPARK project advancing AI-driven drug discovery for Spinocerebellar Ataxia Type 3 and broader neurodegenerative disorders.
- Innosuisse (ORION Project)flagshipPart of ORION, an Innosuisse Flagship project developing an AI-driven microfactory for patient-specific tumor models enabling personalized cancer therapies and accelerating biomarker discovery, drug development and precision oncology.
- USI Startup CentresupportingIncubator location providing startup support, mentorship, and access to academic resources at Università della Svizzera Italiana in Lugano.
- NVIDIAsupportingTechnology supporter providing GPU computing infrastructure for AI model training and molecular simulations.
- Google CloudsupportingCloud infrastructure partner for AI platform deployment and computational workloads.
- Microsoft AzuresupportingCloud infrastructure partner for AI platform deployment and computational workloads.
- Amazon Web ServicessupportingCloud infrastructure partner for AI platform deployment and computational workloads.
- Swiss Startup AssociationsupportingIndustry association providing startup ecosystem support and visibility.
- Fondazione AgiresupportingFoundation supporting innovative startups through acceleration programs like Boldbrain.
Scale indicators13 records
Recent moves6 records
Expansion highlights5 records
InVirtuoLabs competitors and assessment
Company assessmentDirect peers
- XtalPi: AI + physics-based drug discovery platform combining quantum physics, molecular dynamics and ML for crystal structure prediction and small molecule design. Highly comparable integrated ML + physics architecture to InVirtuoLabs' InVirtuoMOL + InVirtuoGEN + InVirtuoSIM stack.
- Atomwise: AI small molecule design company using structure-based deep learning for hit discovery and lead optimization. Directly comparable in silico-first discovery approach with pharma partnership model.
- BenevolentAI: AI drug discovery platform combining biomedical knowledge graphs with ML for target identification and drug repurposing. Comparable platform-play business model targeting pharma enterprise partnerships.
- Insilico Medicine: AI-driven drug discovery platform combining generative chemistry, target identification and deep biology. Directly comparable to InVirtuoLabs' InVirtuo Platform in combining multimodal generative AI with target-to-preclinical workflows; significantly larger and more capitalized with clinical-stage assets.
- Exscientia: AI-driven small molecule drug discovery company with platform combining generative chemistry, active learning and experimental automation. Most direct head-to-head competitor in AI-enabled end-to-end small molecule discovery, with established pharma partnerships.
Broad incumbents
- Recursion Pharmaceuticals: TechBio combining high-throughput wet-lab experimentation with ML for drug discovery. Comparable end-to-end discovery thesis to InVirtuoLabs but emphasizes experimental data generation and phenotypic screening rather than generative chemistry-first design.
- Schrödinger: Public computational chemistry and molecular simulation platform with both software and collaborative drug discovery offerings. Overlaps with InVirtuoLabs on physics-based simulation + ML, but operates at much greater scale with a broader software portfolio serving pharma across discovery and materials science.
- Isomorphic Labs: Alphabet-owned AI drug discovery company building on DeepMind's AlphaFold with end-to-end drug design capabilities. Represents the well-capitalized frontier competitor in AI-native drug discovery that InVirtuoLabs benchmarks against.
Emerging players
- Iambic Therapeutics: AI-driven drug discovery combining physics-based modeling with neural networks for small molecule design. Closely comparable technology stack and emerging-stage positioning relative to InVirtuoLabs.
Others
- ChemAxon: Cheminformatics software platform providing molecular modeling toolkits used widely in pharma drug discovery workflows. Adjacent infrastructure provider whose tools overlap with InVirtuoMOL's molecular property evaluation capabilities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
InVirtuoLabs social profiles
Digital presenceInVirtuoLabs financial estimates
Financial estimateRevenue estimate
Valuation estimate
InVirtuoLabs leadership team
Management profileNumber of profiles
Profiles19 records
InVirtuoLabs funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
InVirtuoLabs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about InVirtuoLabs
What does InVirtuoLabs do?
InVirtuoLabs builds and operates the InVirtuo Platform, an AI-powered end-to-end drug discovery system that combines multimodal learning, active learning, and generative chemistry with physics-based molecular simulations. The platform is delivered as three integrated modules — InVirtuoMOL (molecular property evaluation ML engine), InVirtuoGEN (multimodal generative AI for novel molecule design, capable of generating 1 billion molecules per day), and InVirtuoSIM (physics-based modeling of drug-target interactions) — applied through co-development partnerships with pharmaceutical and biotech companies to identify and optimize preclinical drug candidates.
Is InVirtuoLabs a public or private company?
InVirtuoLabs is a private company. It is classified as venture growth investor backed and is currently operating.
When was InVirtuoLabs founded?
InVirtuoLabs was founded in 2024. It employs 11 to 50 people.
Where is InVirtuoLabs based?
InVirtuoLabs is headquartered in Lugano, Switzerland, in the Europe region.
How does InVirtuoLabs make money?
Three revenue lines are on record. AI Platform Licensing & Co-Development is the primary driver. The others are eurostars Research Grant and euroHPC Access Grant.
Who are InVirtuoLabs's main competitors?
Direct peers on record are XtalPi, Atomwise, BenevolentAI, Insilico Medicine and Exscientia. Broad incumbents are Recursion Pharmaceuticals, Schrödinger and Isomorphic Labs. Iambic Therapeutics is listed as an emerging player. ChemAxon is listed as an others.
Does InVirtuoLabs have an API?
No public API is recorded for InVirtuoLabs.
What industry is InVirtuoLabs in?
InVirtuoLabs's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAE, Cheminformatics & Molecular Modeling / CADD. Its NAICS code is 541714 and its SIC code is 7372.